NeuroSense Therapeutics Ltd.
NRSN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875091
No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.
Other share classesNRSNW
Q1 2023 vs. Q4 2022
How the institutions holding NeuroSense Therapeutics Ltd. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 5 | 5 | 0 |
| Shares | 34.7K | 123.8K | +89.1K (+256.9%) |
| Value | $41.6K | $243.4K | +$201.7K (+484.7%) |
New holders (2)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Meitav Dash Investments Ltd | 95,000 | $193.3K | 0.00% |
| Ground Swell Capital, LLC | 11,858 | $20.6K | 0.03% |
Sold out (2)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Renaissance Technologies LLC | 18,433 | $22.0K |
| Morgan Stanley | 4 | $5 |